Adjuvant therapy for pancreas adenocarcinoma

Journal of Surgical Oncology

Volumn 107, Issue 1, 2013, Pages 78-85

  O'Reilly, Eileen M ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

adjuvant; biomarker; chemoradiotherapy; erlotinib; gemcitabine; immunotherapy; pancreas adenocarcinoma

Indexed keywords

ALGENPANTUCEL L; ALPHA INTERFERON; BEVACIZUMAB; CALVASCULIN; CAPECITABINE; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOMYCIN; OXALIPLATIN; SMAD4 PROTEIN; T LYMPHOCYTE ANTIGEN; TERTOMOTIDE;

ADJUVANT CHEMORADIOTHERAPY; ARTICLE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CELL ACTIVATION; CYTOLYSIS; CYTOTOXICITY; DECISION MAKING; DISEASE FREE SURVIVAL; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HEMATOLOGIC DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MEDICAL RECORD REVIEW; METABOLIC DISORDER; MOLECULAR BIOLOGY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RECURRENCE FREE SURVIVAL; SACCHAROMYCES CEREVISIAE; WILD TYPE;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; HUMANS; IMMUNOTHERAPY; PANCREATIC NEOPLASMS; QUINAZOLINES; TREATMENT OUTCOME;

EID: 84871303283     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23230     Document Type: Article

References (76)

1. Ghaneh P, Costello E, Neoptolemos JP:, Biology and management of pancreatic cancer. Gut 2007; 56: 1134-1152.
2. Garcea G, Dennison AR, Pattenden CJ, et al.: Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP 2008; 9: 99-132.
3. Ferrone CR, Brennan MF, Gonen M, et al.: Pancreatic adenocarcinoma: The actual 5-year survivors. J Gastrointest Surg 2008; 12: 701-706.
4. Gudjonsson B:, Cancer of the pancreas. 50 years of surgery. Cancer 1987; 60: 2284-2303.
5. Iacobuzio-Donahue CA, Fu B, Yachida S, et al.: DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009; 27: 1806-1813.
6. Van den Broeck A, Sergeant G, Ectors N, et al.: Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol 2009; 35: 600-6604.
7. Tepper J, Nardi G, Sutt H:, Carcinoma of the pancreas: Review of MGH experience from 1963 to 1973 Analysis of surgical failure and implications for radiation therapy. Cancer 1976; 37: 1519-1524.
8. Rozenblum E, Schutte M, Goggins M, et al.: Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997; 57: 1731-1734.
9. Biankin AV, Morey AL, Lee CS, et al.: DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol 2002; 20: 4531-4542.
10. Crane CH, Varadhachary GR, Yordy JS, et al.: Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: Correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 2011; 29: 3037-3043.
11. Jones S, Zhang X, Parsons DW, et al.: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (New York, NY) 2008; 321: 1801-1806.
12. Kalser MH, Ellenberg SS:, Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120: 899-903.
13. Bakkevold KE, Arnesjo B, Dahl O, et al.: Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater-Results of a controlled, prospective, randomised multicentre study. Eur J Cancer 1993; 29A: 698-703.
14. Kosuge T, Kiuchi T, Mukai K, et al.: A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol 2006; 36: 159-165.
15. Klinkenbijl JH, Jeekel J, Sahmoud T, et al.: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230: 776-782; discussion 782-774.
16. Neoptolemos JP, Dunn JA, Stocken DD, et al.: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomised controlled trial. Lancet 2001; 358: 1576-1585.
17. Neoptolemos JP, Stocken DD, Friess H, et al.: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210.
18. Abrams RA, Lillemoe KD, Piantadosi S:, Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet 2001; 358: 1565-1566.
19. Evans DB, Hess KR, Pisters PW:, ESPAC-1 trial of adjuvant therapy for resectable adenocarcinoma of the pancreas. Ann Surg 2002; 236: 694; author reply 694-696.
20. Choti MA:, Adjuvant therapy for pancreatic cancer-The debate continues. N Engl J Med 2004; 350: 1249-1251.
21. Oettle H, Post S, Neuhaus P, et al.: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 2007; 297: 267-277.
22. Neuhaus P, Riess H, Post S, et al.: CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol (Meeting Abstracts) 2008; 26: LBA4504.
23. Neoptolemos JP, Stocken DD, Bassi C, et al.: Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA 2010; 304: 1073-1081.
24. Regine WF, Winter KA, Abrams RA, et al.: Fluorouracil vs. gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial. JAMA 2008; 299: 1019-1026.
25. Abrams RA, Winter KA, Regine WF, et al.: 39: RTOG 9704 Radiotherapy Quality Assurance (QA) review and survival. Int J Radiat Oncol Biol Phys 2006; 66: S22.
26. Berger AC, Garcia M, Jr., Hoffman JP, et al.: Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: A prospective validation by RTOG 9704. J Clin Oncol 2008; 26: 5918-5922.
27. Humphris JL, Chang DK, Johns AL, et al.: The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol 2012; 1713-1722.
28. Redmond KJ, Wolfgang CL, Sugar EA, et al.: Adjuvant chemoradiation therapy for adenocarcinoma of the distal pancreas. Ann Surg Oncol 2010; 17: 3112-3119.
29. Krishnan S, Rana V, Janjan NA, et al.: Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 2007; 110: 47-55.
30. Ko AH, Quivey JM, Venook AP, et al.: A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2007; 68: 809-816.
31. Mukherjee S, Hudson E, Reza S, et al.: Pancreatic cancer within a UK cancer network with special emphasis on locally advanced non-metastatic pancreatic cancer. Clin Oncol (R Coll Radiol) 2008; 20: 535-540.
32. Huguet F, Andre T, Hammel P, et al.: Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007; 25: 326-331.
33. Van Laethem J, Van Cutsem E, Hammel P, et al.: Adjuvant chemotherapy alone versus chemoradiation after curative resection for pancreatic cancer: Feasibility results of a randomised EORTC/FFCD/GERCOR phase II/III study (40013/22012/0304). J Clin Oncol (Meeting Abstracts) 2008; 26: 4514.
34. Van Laethem JL, Hammel P, Mornex F, et al.: Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: A randomized EORTC-40013-2201 2/FFCD-9203/GERCOR phase II study. J Clin Oncol 2010; 28: 4450-4456.
35. Merchant NB, Rymer J, Koehler EA, et al.: Adjuvant chemoradiation therapy for pancreatic adenocarcinoma: Who really benefits ? J Am Coll Surg 2009; 208: 829-838; discussion 838-841.
36. Corsini MM, Miller RC, Haddock MG, et al.: Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: The Mayo Clinic experience (1975-2005). J Clin Oncol 2008; 26: 3511-3516.
37. Hsu CC, Herman JM, Corsini MM, et al.: Adjuvant chemoradiation for pancreatic adenocarcinoma: The Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol 2010; 17: 981-990.
38. Moore MJ, Goldstein D, Hamm J, et al.: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966.
39. Moore MJ, da Cunha Santos G, Kamel-Reid S, et al.: The relationship of K-ras mutations and EGFR gene copy number to outcome in patients treated with erlotinib on National Cancer Institute of Canada Clinical Trials Group trial study PA.3. J Clin Oncol (Meeting Abstracts) 2007; 25: 4521.
40. Danese MD, Reyes C, Northridge K, et al.: Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer. Clin Ther 2008; 30: 775-7784.
41. Bao P, Ramanathan R, Krasinkas A, et al.: Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer. Ann Surg Oncol 2011; 18: 1122-1129.
42. Berlin J, Catalano PJ, Feng Y, et al.: ECOG 2204: An intergroup randomized phase II study of cetuximab (Ce) or bevacizumab (B) in combination with gemcitabine (G) and in combination with capecitabine (Ca) and radiation (XRT) as adjuvant therapy (Adj Tx) for patients (pts) with completely resected pancreatic adenocarcinoma (PC). ASCO (Meeting Abstracts) 2010; 28: 4034.
43. Kindler HL, Niedzwiecki D, Hollis D, et al.: Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28: 3617-3622.
44. Philip PA, Benedetti J, Corless CL, et al.: Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010; 28: 3605-3610.
45. Conroy T, Desseigne F, Ychou M, et al.: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825.
46. Picozzi VJ:, Novel approaches to postoperative chemoradiation therapy in pancreatic cancer. J Gastrointest Surg 2001; 5: 8-9.
47. Picozzi VJ, Abrams RA, Decker PA, et al.: Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol 2011; 2: 348-354.
48. Linehan DC, Tan MC, Strasberg SM, et al.: Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: A single-institution phase II study. Ann Surg 2008; 248: 145-151.
49. Knaebel HP, Marten A, Schmidt J, et al.: Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma CapRI: Study protocol [ISRCTN62866759]. BMC Cancer 2005; 37.
50. Marten A, Schmidt J, Debus J, et al.: CapRI: Final results of the open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon-{alpha}2b (CRI) versus 5-FU alone for patients with resected pancreatic adenocarcinoma (PAC). ASCO (Meeting Abstracts) 2010; 28: LBA4012.
51. Laheru D, Jaffee EM:, Immunotherapy for pancreatic cancer-Science driving clinical progress. Nat Rev 2005; 5: 459-467.
52. Laheru DA, Pardoll DM, Jaffee EM:, Genes to vaccines for immunotherapy: How the molecular biology revolution has influenced cancer immunology. Mol Cancer Ther 2005; 4: 1645-1652.
53. Weden S, Klemp M, Gladhaug IP, et al.: Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer 2011; 128: 1120-1128.
54. Abou-Alfa GK, Chapman PB, Feilchenfeldt J, et al.: Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. Am J Clin Oncol 2011; 3: 321-325.
55. Shaw VE, Naisbitt DJ, Costello E, et al.: Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer. Expert Rev Vaccines 2010; 9: 1007-1016.
56. Bernhardt SL, Gjertsen MK, Trachsel S, et al.: Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer 2006; 95: 1474-1482.
57. Buanes T, Maurel J, Liauw W, et al.: A randomized phase III study of gemcitabine (G) versus GV1001 in sequential combination with G in patients with unresectable and metastatic pancreatic cancer (PC). ASCO (Meeting Abstracts) 2009; 27: 4601.
58. Wobser M, Keikavoussi P, Kunzmann V, et al.: Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 2006; 55: 1294-1298.
59. Jaffee EM, Hruban RH, Biedrzycki B, et al.: Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation. J Clin Oncol 2001; 19: 145-156.
60. Lutz E, Yeo CJ, Lillemoe KD, et al.: A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg 2011; 253: 328-335.
61. Laheru D, Lutz E, Burke J, et al.: Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: A pilot study of safety, feasibility, and immune activation. Clin Cancer Res 2008; 14: 1455-1463.
62. Link CJ Jr, Seregina T, Atchison R, et al.: Eliciting hyperacute xenograft response to treat human cancer: Alpha(1,3) galactosyltransferase gene therapy. Anticancer Res 1998; 18: 2301-2308.
63. Galili U, LaTemple DC:, Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. Immunol Today 1997; 18: 281-285.
64. LaTemple DC, Abrams JT, Zhang SY, et al.: Increased immunogenicity of tumor vaccines complexed with anti-Gal: Studies in knockout mice for alpha1,3galactosyltransferase. Cancer Res 1999; 59: 3417-3423.
65. Hardacre JM, Mulcahy MF, Talamonti M, et al.: Effect of hyperacute immunotherapy in addition to standard adjuvant therapy for resected pancreatic cancer on disease-free and overall survival: Preliminary analysis of phase II data. ASCO (Meeting Abstracts) 2010; 28: 4059.
66. Mackey JR, Baldwin SA, Young JD, et al.: Nucleoside transport and its significance for anticancer drug resistance. Drug Resist Updat 1998; 1: 310-3324.
67. Garcia-Manteiga J, Molina-Arcas M, Casado FJ, et al.: Nucleoside transporter profiles in human pancreatic cancer cells: Role of hCNT1 in 2',2'-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res 2003; 9: 5000-5008.
68. Mori R, Ishikawa T, Ichikawa Y, et al.: Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. Oncol Rep 2007; 17: 1201-1205.
69. Farrell JJ, Elsaleh H, Garcia M, et al.: Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009; 136: 187-195.
70. Mahon PC, Baril P, Bhakta V, et al.: S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer. Cancer Res 2007; 67: 6786-6795.
71. Biankin AV, Kench JG, Colvin EK, et al.: Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology 2009; 137: 558-568 568 e551-511.
72. Tempero MA, Moughan J, Kim GE, et al.: S100A4 as a biomarker of resistance to gemcitabine: A secondary analysis of RTOG 9704. ASCO (Meeting Abstracts) 2012; 30: 165.
73. Neoptolemos JP, Stocken DD, Tudur Smith C, et al.: Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: Composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer 2009; 100: 246-250.
74. Lowy AM:, Neoadjuvant therapy for pancreatic cancer. J Gastrointest Surg 2008; 12: 1600-1608.
75. Nugent FW, Stuart K:, Adjuvant and neoadjuvant therapy in curable pancreatic cancer. Surg Clin North Am 2010; 90: 323-339.
76. Von Hoff DD, Ramanathan RK, Borad MJ, et al.: Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase I/II trial. J Clin Oncol 2011; 29: 4548-4554.